SG11201900515PA - Succinate forms and compositions of bruton's tyrosine kinase inhibitors - Google Patents

Succinate forms and compositions of bruton's tyrosine kinase inhibitors

Info

Publication number
SG11201900515PA
SG11201900515PA SG11201900515PA SG11201900515PA SG11201900515PA SG 11201900515P A SG11201900515P A SG 11201900515PA SG 11201900515P A SG11201900515P A SG 11201900515PA SG 11201900515P A SG11201900515P A SG 11201900515PA SG 11201900515P A SG11201900515P A SG 11201900515PA
Authority
SG
Singapore
Prior art keywords
international
bruton
compositions
suite
pct
Prior art date
Application number
SG11201900515PA
Inventor
J Michael Macphee
Linda L Neuman
Original Assignee
Biogen Ma Inc
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc, Sunesis Pharmaceuticals Inc filed Critical Biogen Ma Inc
Publication of SG11201900515PA publication Critical patent/SG11201900515PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

PUBLISHEDUNDER THE PATENT COOPERATION TREATY (PCT) °Ens °nolo omm olowolioliono oimIE () International Publication Number WO 2018/017153 Al WIPO I PCT (12) INTERNATIONAL APPLICATION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 January 2018 (25.01.2018) (51) International Patent Classification: CO7D 401/14 (2006.01) A61P 37/02 (2006.01) A61K 31/445 (2006.01) (21) International Application Number: PCT/US2017/012637 (22) International Filing Date: 06 January 2017 (06.01.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/365,353 21 July 2016 (21.07.2016) US 62/385,202 08 September 2016 (08.09.2016) US (71) Applicants: BIOGEN MA INC. [US/US]; 250 Binney Street, Cambridge, Massachusetts 02142 (US). SUNESIS PHARMACEUTICALS, INC. [US/US]; 395 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: MACPHEE, J. Michael; c/o Biogen MA Inc., 250 Binney Street, Cambridge, Massachusetts 02142 (US). NEUMAN, Linda L.; c/o Sunesis Pharmaceuticals, Inc., 395 Oyster Point Blvd., Suite 400, South San Francisco, California 94080 (US). (74) Agent: DREIS, Ashley, M. et al.; Cooley LLP, 1299 Penn- sylvania Avenue, NW, Suite 700, Washington, D.C. 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) as to non prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v)) Published: — with international search report (Art. 21(3)) O (57) : The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine 0 kinase and which exhibit desirable characteristics for the same. (54) Title: SUCCINATE FORMS AND COMPOSITIONS OF BRUTON'S TYROSINE KINASE INHIBITORS
SG11201900515PA 2016-07-21 2017-01-06 Succinate forms and compositions of bruton's tyrosine kinase inhibitors SG11201900515PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662365353P 2016-07-21 2016-07-21
US201662385202P 2016-09-08 2016-09-08
PCT/US2017/012637 WO2018017153A1 (en) 2016-07-21 2017-01-06 Succinate forms and compositions of bruton's tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
SG11201900515PA true SG11201900515PA (en) 2019-02-27

Family

ID=57910151

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201900515PA SG11201900515PA (en) 2016-07-21 2017-01-06 Succinate forms and compositions of bruton's tyrosine kinase inhibitors

Country Status (13)

Country Link
US (1) US11174243B2 (en)
EP (1) EP3487852A1 (en)
JP (2) JP7214632B2 (en)
KR (1) KR20190035769A (en)
CN (1) CN110049976A (en)
AU (1) AU2017298035B2 (en)
BR (1) BR112019001158A2 (en)
CA (1) CA3031443A1 (en)
IL (1) IL264341A (en)
MX (1) MX2019000884A (en)
RU (1) RU2019104758A (en)
SG (1) SG11201900515PA (en)
WO (1) WO2018017153A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2473049T3 (en) * 2009-09-04 2019-07-31 Biogen Ma Inc. Bruton's tyrosine kinase inhibitors
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors
US20240197744A1 (en) * 2021-05-12 2024-06-20 The Cleveland Clinic Foundation Treating sex steroid dependent cancer with bmx inhibitors
CN115702898B (en) * 2021-08-04 2024-02-09 成都倍特药业股份有限公司 BTK inhibitor solid preparation and preparation method thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4528138A (en) 1984-06-20 1985-07-09 E. R. Squibb & Sons, Inc. 16-Keto-17-substituted thia-17-alkyl(or alkenyl or alkynyl) androstenes
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (en) 1985-10-03 1988-12-02 Merck Sharp & Dohme LIQUID-GEL PHASE TRANSITION PHARMACEUTICAL COMPOSITION
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
PA8474101A1 (en) 1998-06-19 2000-09-29 Pfizer Prod Inc PYROLEUM [2,3-D] PIRIMIDINE COMPOUNDS
US6919178B2 (en) 2000-11-21 2005-07-19 Sunesis Pharmaceuticals, Inc. Extended tethering approach for rapid identification of ligands
AU2001250849A1 (en) 2000-03-17 2001-10-03 Bristol-Myers Squibb Pharma Company Cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
MY145722A (en) 2000-04-27 2012-03-30 Abbott Lab Diazabicyclic central nervous system active agents
PT1294724E (en) 2000-06-26 2006-07-31 Pfizer Prod Inc COMPOUNDS PYRROLE (2,3-D) PYRIMIDINE AS IMMUNOSPRESSOR AGENTS
PE20020507A1 (en) 2000-10-17 2002-06-25 Schering Corp NON-IMIDAZOLE COMPOUNDS AS ANTAGONISTS OF THE HISTAMINE H3 RECEPTOR
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
JP2005515173A (en) 2001-10-31 2005-05-26 バイエル・ヘルスケア・アクチェンゲゼルシャフト Pyrimido [4,5-b] indole derivatives
US7276021B2 (en) 2001-10-31 2007-10-02 Paracor Medical, Inc. Heart failure treatment device and method
UA92450C2 (en) 2003-01-14 2010-11-10 Арена Фармасьютикалз, Инк. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7326712B2 (en) 2003-10-14 2008-02-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Substituted tricyclic compounds as protein kinase inhibitors
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
FR2870541B1 (en) 2004-05-18 2006-07-14 Proskelia Sas ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR
TW200621760A (en) 2004-09-09 2006-07-01 Mitsubishi Pharma Corp 2-morpholino-4-pyrimidone compound
CA2586375A1 (en) 2004-11-04 2006-05-18 Juan-Miguel Jimenez Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
JP5274842B2 (en) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド [1H-piperazo [3,4-d] pyrimidin-4-yl] -piperazine as a serine-threonine kinase modulator (p70S6K, Akt-1 and Akt-2) for the treatment of immune, inflammatory and proliferative disorders Or [1H-piperazo [3,4-d] pyrimidin-4-yl] -piperazine compounds
WO2006071875A1 (en) 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006091450A1 (en) 2005-02-18 2006-08-31 Lexicon Genetics Incorporated 4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
US20060281764A1 (en) 2005-06-10 2006-12-14 Gaul Michael D Aminopyrimidines as kinase modulators
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
TW200740779A (en) 2005-07-22 2007-11-01 Mitsubishi Pharma Corp Intermediate compound for synthesizing pharmaceutical agent and production method thereof
US7528143B2 (en) 2005-11-01 2009-05-05 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
JP2009521445A (en) 2005-12-21 2009-06-04 シェーリング コーポレイション Combination of H3 antagonist / inverse agonist and appetite suppressant
WO2008005368A2 (en) 2006-06-30 2008-01-10 Abbott Laboratories Piperazines as p2x7 antagonists
WO2008012635A2 (en) 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
KR20090046872A (en) 2006-07-26 2009-05-11 노파르티스 아게 Inhibitors of undecaprenyl pyrophosphate synthase
JP2010502751A (en) 2006-09-11 2010-01-28 シージーアイ ファーマシューティカルズ，インコーポレイティド Kinase inhibitors and methods of using and identifying kinase inhibitors
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
MX2009009417A (en) 2007-03-02 2009-09-11 Schering Corp Piperidinyl-piperidine and piperazinyl-piperidine for use in the treatment of diabetes or pain.
CN101730699A (en) 2007-03-21 2010-06-09 百时美施贵宝公司 Can be used for treating the condensed heterocyclic compouds of proliferative, allergy, autoimmunity and diseases associated with inflammation
WO2008144253A1 (en) 2007-05-14 2008-11-27 Irm Llc Protein kinase inhibitors and methods for using thereof
JP5291095B2 (en) 2007-06-01 2013-09-18 グラクソスミスクライン エルエルシー Imidazopyridine kinase inhibitor
DK2242749T3 (en) 2008-02-05 2013-06-17 Hoffmann La Roche NEW PYRIDINONES AND PYRIDAZINONES
US8617823B2 (en) 2008-04-29 2013-12-31 Immunexcite, Inc. Immunomodulating compositions and methods of use thereof
EP2307025B1 (en) 2008-07-16 2017-09-20 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
CN102325753B (en) 2008-12-19 2014-09-10 百时美施贵宝公司 Carbazole carboxamide compounds useful as kinase inhibitors
EP3255047B1 (en) 2009-01-06 2021-06-30 Dana-Farber Cancer Institute, Inc. Pyrimido-diazepinone kinase scaffold compounds and uses in treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
EP2435442B1 (en) 2009-05-25 2016-01-13 Sandoz AG Method for producing ceftobiprol medocaril
EP2485589A4 (en) 2009-09-04 2013-02-06 Biogen Idec Inc Heteroaryl btk inhibitors
PL2473049T3 (en) 2009-09-04 2019-07-31 Biogen Ma Inc. Bruton's tyrosine kinase inhibitors
US8685880B2 (en) 2010-06-30 2014-04-01 Chevron U.S.A. Inc. On-site drying of aqueous salt for ionic liquid make-up
EP2632898A4 (en) 2010-10-29 2014-04-02 Biogen Idec Inc Heterocyclic tyrosine kinase inhibitors
WO2013185082A2 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Inhibitors of bruton's tyrosine kinase
AR091273A1 (en) * 2012-06-08 2015-01-21 Biogen Idec Inc PYRIMIDINYL TIROSINE KINASE INHIBITORS
US10280169B2 (en) 2013-12-11 2019-05-07 Biogen Ma Inc. Biaryl bruton's tyrosine kinase inhibitors
CN108947913A (en) 2013-12-11 2018-12-07 比奥根Ma公司 It can be used for treating the aryl-linking compound of human tumor, neurology and amynologic disease
US20170298446A1 (en) 2014-10-03 2017-10-19 Ohio State Innovation Foundation Biomarkers of bruton tyrosine kinase inhibitor resistance
US11174243B2 (en) 2016-07-21 2021-11-16 Sunesis Pharmaceuticals, Inc. Succinate forms and compositions of Bruton's tyrosine kinase inhibitors

Also Published As

Publication number Publication date
WO2018017153A1 (en) 2018-01-25
JP7214632B2 (en) 2023-01-30
JP2019525960A (en) 2019-09-12
CA3031443A1 (en) 2018-01-25
IL264341A (en) 2019-02-28
US11174243B2 (en) 2021-11-16
JP2023052462A (en) 2023-04-11
KR20190035769A (en) 2019-04-03
AU2017298035B2 (en) 2021-10-28
RU2019104758A (en) 2020-08-21
AU2017298035A1 (en) 2019-03-14
US20210032218A1 (en) 2021-02-04
RU2019104758A3 (en) 2020-08-21
EP3487852A1 (en) 2019-05-29
CN110049976A (en) 2019-07-23
BR112019001158A2 (en) 2019-04-30
MX2019000884A (en) 2019-09-04

Similar Documents

Publication Publication Date Title
SG11201909949XA (en) Targeted immunotolerance
SG11201908820VA (en) Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201805532XA (en) Multivalent and multispecific 41bb-binding fusion proteins
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201811151PA (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201808990QA (en) Compositions for topical application of compounds
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201906891RA (en) Methods for the administration of certain vmat2 inhibitors
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201807720TA (en) Methods and systems for determining antibiotic susceptibility
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201809751XA (en) Egfr inhibitor compounds
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201903061YA (en) Combination treatments comprising administration of imidazopyrazinones
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same